Efficacy and tolerability of PCSK9 inhibitors in real-world clinical practice

Despite widespread use of statins and other lipid-lowering therapies for hypercholesterolaemia, cardiovascular (CV) mortality and morbidity remains high. The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, have been approved for use in patients with famil...

Full description

Saved in:
Bibliographic Details
Published inThe British journal of cardiology Vol. 30; no. 4
Main Authors Devaiah, Prashasthi, Handjiev, Sava, George, Jacob
Format Journal Article
LanguageEnglish
Published Medinews (Cardiology) Limited 01.01.2023
Subjects
Hypercholesterolaemia
Online AccessGet full text

Cover

More Information
Summary:Despite widespread use of statins and other lipid-lowering therapies for hypercholesterolaemia, cardiovascular (CV) mortality and morbidity remains high. The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, have been approved for use in patients with familial hypercholesterolaemia and high CV risk in the UK. We reviewed the records of patients at a large health board in Scotland, who were prescribed these agents, to determine their real- world efficacy and tolerability in routine clinical care.
ISSN:0969-6113
1753-4313
DOI:10.5837/bjc.2023.044